Scientific contributions
Co-author on peer-reviewed and conference contributions spanning HTA, AMNOG, market access, real-world evidence, rare disease and clinical data management.
Health technology assessment, early benefit assessment and pricing analysis in the German healthcare system.
Changes and implications for the reference price grouping according to §35 SGB V under the Pharmaceutical Care Strengthening Act in Germany
Eheberg D, Batscheider A, Schmalhofer C, Gossmann J, Antoni B
Implications of the German HTA-process on market-uptake of oral treatments for type-2-diabetes (T2DM) since 2007 (PDB69)
Greiner RA, Fischer T, Antoni B, Batscheider A
Comparative analysis of the market penetration of personalized medicine drugs under the conditions of AMNOG
Fischer T., Bonduelle D., Antoni B.
Overview of German AMNOG dossiers with price analysis before and after early benefit assessment
Tremmel M, Batscheider A, Bocuk D, Roxlau T, Antoni B, Mihaylova E, Bonduelle D
The impact of label extensions on the reimbursed price of pharmaceutical products assessed according to §35a SGB V in Germany — oncological and metabolic diseases
Schmalhofer C, Eheberg D, Tremmel M, Bocuk D, Roxlau T, Antoni B, Bonduelle D
Originator and generic market access protection strategies in Germany using dermatology as an example
Greiner RA, Batscheider A, Antoni B, Hinnenthal M, Bonduelle D
Potential influence of HTA on price outcomes of non-orphan pharmaceuticals in the German AMNOG process
Pointner J, Tremmel M, Antoni B, Kuschel A, Eheberg D, Bonduelle D
Analysis of the relationship between Health Technology Assessment (HTA) evaluation and reimbursed price of HIV combination drugs in EU-3 (France, Germany, UK)
Roxlau T, Batscheider A, Lukas M, Antoni B, Schwarzhans JP, Greiner RA, Bonduelle D
Biosimilars and reference price groups in Germany
Eheberg D, Pointner J, Antoni B, Gossmann J
Market uptake, observational data and electronic medical record enriched study designs.
Market uptake of direct oral anticoagulants (DOACs) in Germany
Batscheider A, Greese B, Dannemann S, Gaba D, Paulus G, Antoni B, Stöcker P, Peters A, Greiner RA
Evaluation of a novel enriched study approach to complement electronic medical records (EMR)
Smieszek T, von Bredow D, Kunz T, Piesch S, Antoni B, Winkler I, Röckel T, Engelhard J
Retrospective chart review studies in Germany contributing to the evidence base for a rare lysosomal storage disorder.
Survival analysis of acid sphingomyelinase deficiency (ASMD) patients in Germany: A retrospective chart review study
Mengel E, Muschol N, Weinhold N, Ziagaki A, Antoni B, Langer L, Gasparic M, Guillonneau S, Laredo F, Pulikottil-Jacob R• 2022
Burden of Illness of acid sphingomyelinase deficiency (ASMD): A retrospective chart review study in Germany
Mengel E, Muschol N, Weinhold N, Ziagaki A, Antoni B, Langer L, Gasparic M, Guillonneau S, Laredo F, Pulikottil-Jacob R• 2022
A retrospective study of morbidity and mortality of chronic acid sphingomyelinase deficiency in Germany
Mengel E, Muschol N, Weinhold N, Ziagaki A, Neugebauer J, Antoni B, Langer L, Gasparic M, Guillonneau S, Fournier M, Laredo F, Pulikottil-Jacob R• 2024
Data quality, hospital leadership metrics and clinical data management foundations.
Geringe Korrelation von Krankenhausführern kann zu verwirrenden Ergebnissen führen
Thielscher C, Antoni B, Driedger J, Jacobi S, Krol B• 2014• Georg Thieme Verlag KG Stuttgart, 19(2): 65–69
Need the full reference list?
Download the complete publications overview as a PDF.